INNOVATION AND BENEFITS
The two main innovations under development by PCITP are: (1) a MiHA targeted T-cell therapy and (2) a molecular test for predicting the risk of GVHD and donor selection could ultimately contribute to curative treatment of patients with haematological cancers (HCs) including leukemia, lymphoma and myeloma.
Each year in Canada 16,000 people are diagnosed with HC. This results in a loss of 60,000 potential life-years and represents $ 5 B in direct and indirect costs. Chemotherapy and radiation therapy are successful in treating only 50% of patients with HCs. The only treatment option for the remaining 50% is allogenic hematopoietic cell transplantation (AHCT). Unfortunately, AHCT is a high risk procedure with a 50-60% chance of developing GVHD which is lethal in 25% of cases. As a result, although potentially curative, AHCT is used only in 20% of eligible patients. Major clinical and economic benefits can thus be generated if PCITP is successful in its development efforts.
The timely success of the PCITP project depends not only on the clinical and scientific expertise brought to bear but also on the ability of the research team, its partners and collaborators to plan, execute and fund the clinical development and clinical adoption of the MiHA T-cell therapy and GVHD predictive test. PCITP includes ongoing research focused on defining barriers that the project will encounter as it proceeds through clinical development, commercialization and clinical implementation – GE3LS research (Genomics & its Ethical, Environmental, Economic, Legal and Social Aspects).